BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gigi E, Lagopoulos VI, Bekiari E. Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. World J Hepatol 2018; 10(9): 595-602 [PMID: 30310537 DOI: 10.4254/wjh.v10.i9.595] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Lin D, Reddy V, Osman H, Lopez A, Koksal AR, Rhadhi SM, Dash S, Aydin Y. Additional Inhibition of Wnt/β-Catenin Signaling by Metformin in DAA Treatments as a Novel Therapeutic Strategy for HCV-Infected Patients. Cells 2021;10:790. [PMID: 33918222 DOI: 10.3390/cells10040790] [Reference Citation Analysis]
2 Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol 2022; 28(1): 140-153 [DOI: 10.3748/wjg.v28.i1.140] [Reference Citation Analysis]
3 Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31:953-60. [PMID: 32376182 DOI: 10.1016/j.jvir.2019.12.809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Xiao Y, Chen B, Yang K, Wang Q, Liu P, Gu Y, Zhong Q, Liu Z, He Y, Liu Q. Down-regulation of MARCO associates with tumor progression in hepatocellular carcinoma. Exp Cell Res 2019;383:111542. [PMID: 31381879 DOI: 10.1016/j.yexcr.2019.111542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]
7 Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. Sci Rep 2019;9:17081. [PMID: 31745132 DOI: 10.1038/s41598-019-53051-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
8 Ke PY. The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. Int J Mol Sci 2018;19:E3940. [PMID: 30544615 DOI: 10.3390/ijms19123940] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]